IL-31 and IL-8 in Cutaneous T-Cell Lymphoma: Looking for Their Role in Itch

Table 2

Laboratorial features of the CTCL study population, at the time of the study.

Blood cell counts and cytomorphology
Leucocytes (x109/L)	7.30 (4.50–130.70)
Neutrophils (x109/L)	4.28 (1.84–15.82)
Lymphocytes (x109/L)	2.34 (0.20–96.20)
Monocytes (x109/L)	0.57 (0.08–17.25)
Hemoglobin (g/dL)	13.7 (8.6–16.5)
Platelets (x109/L)	220 (42–357)
Atypical lymphocytes/SC (% leucocytes)	0.0 (0.0–66.5)
Abnormal blood cell counts
Leukocytosis (>11 × 10^9/L)	3/27 (11.1%)
Neutrophilia (>7.0 × 10^9/L); neutropenia (<1.5 × 10^9/L)	1/27 (3.7%); 0/27 (0.0%)
Lymphocytosis (>3.5 × 10^9/L); lymphopenia (<1.5 × 10^9/L)	3/27 (11.1%); 9/27 (33.3%)
Anemia (hg < 12.0 g/dL)	7/27 (25.9%)
Thrombocytopenia (<100 × 10^9/L)	1/27 (3.7%)
Lymphocyte immunophenotyping
CD4+ T-cell count/μL	930 (23–93329)
CD4/CD8 ratio	2.8 (0.6–99.0)
Phenotypically abnormal CD4+ SC
% CD4+ T cells	0.0 (0.0–98.0)
% leucocytes	0.0 (0.0–70.7)
Cell counts/μl	0 (0–92395)
Blood involvement
Yes	11 (40.7%)
Stage B0 (SC < 5% lymphocytes)	17 (62.9%) †
Stage B1 (SC > 5% lymphocytes, <1000 CS/μL)	5 (18.5%)
Stage B2 (SC > 1000 CS/μL)	5 (18.5%)
Biochemistry
B2MG (mg/L)	2.10 (1.20–14.70)
Increased B2MG (>2.53 mg/L)	8/23 (34.8%)
LDH (U/L)	224 (128–656)
Increased LDH (>225 U/L)	11/22 (50.0%)
Abnormal liver tests	2/27 (67.4%)
Abnormal kidney tests	1/27 (3.7%)

Results are presented as median (range) and as absolute and relative frequencies. CTCL, cutaneous T-cell lymphoma; CS, Sézary cells; B2MG, beta 2 microglobulin; LDH, lactate dehydrogenase; MF, Mycosis Fungoides; SS, Sézary syndrome. One patient had circulating CD4+ SC, although they represent only 2.9% of CD4+ T cells, 1.8% of lymphocytes, and 0.4% of leukocytes.